MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
68.57
+1.49 (2.22%)
Aug 14, 2026, 4:00 PM EDT - Market closed
MBX Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 54.12 | 75.29 | 49.35 | 30.52 | 24.21 |
Short-Term Investments | 364.46 | 298.42 | 212.8 | 50.15 | 18.25 |
Cash & Short-Term Investments | 418.58 | 373.71 | 262.15 | 80.68 | 42.46 |
Cash Growth | 86.11% | 42.55% | 224.94% | 90.00% | - |
Other Receivables | 3.04 | 2.12 | 0.68 | 0.21 | 0.14 |
Receivables | 3.04 | 2.12 | 0.68 | 0.21 | 0.14 |
Prepaid Expenses | 5.07 | 4.85 | 3.65 | 2.45 | 1.52 |
Other Current Assets | 1.16 | 0.86 | 0.8 | 0.13 | 0.08 |
Total Current Assets | 427.86 | 381.54 | 267.29 | 83.47 | 44.21 |
Property, Plant & Equipment | 7.42 | 3.22 | 1.2 | 0.67 | 0.84 |
Other Long-Term Assets | 0.25 | 0.38 | 0.05 | 0.05 | 0.04 |
Total Assets | 435.91 | 385.14 | 268.54 | 84.18 | 45.1 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 4.36 | 2.98 | 5.34 | 1.39 | 0.98 |
Accrued Expenses | 18.67 | 12.35 | 5.55 | 2.38 | 2.32 |
Current Portion of Leases | 0.63 | 0.17 | 0.17 | 0.15 | 0.14 |
Total Current Liabilities | 23.66 | 15.5 | 11.05 | 3.93 | 3.43 |
Long-Term Leases | 2.71 | 0.42 | - | 0.17 | 0.32 |
Other Long-Term Liabilities | - | 0 | 0.04 | 0.19 | 0.07 |
Total Liabilities | 26.37 | 15.92 | 11.09 | 4.29 | 3.82 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-In Capital | 695.84 | 593.41 | 394.89 | 3.05 | 0.41 |
Retained Earnings | -285.09 | -224.48 | -137.51 | -75.58 | -43.02 |
Comprehensive Income & Other | -1.22 | 0.29 | 0.06 | 0.06 | 0 |
Total Common Equity | 409.54 | 369.22 | 257.44 | -72.47 | -42.61 |
Shareholders' Equity | 409.54 | 369.22 | 257.44 | 79.89 | 41.27 |
Total Liabilities & Equity | 435.91 | 385.14 | 268.54 | 84.18 | 45.1 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 3.34 | 0.6 | 0.17 | 0.32 | 0.46 |
Net Cash (Debt) | 415.24 | 373.11 | 261.98 | 80.35 | 42 |
Net Cash Growth | 85.16% | 42.42% | 226.04% | 91.31% | - |
Net Cash Per Share | 9.58 | 10.22 | 24.62 | 78.87 | 62.97 |
Filing Date Shares Outstanding | 48.16 | 47.51 | 33.42 | 1.26 | 0.67 |
Total Common Shares Outstanding | 47.95 | 44.93 | 33.42 | 1.26 | 0.67 |
Working Capital | 404.2 | 366.04 | 256.24 | 79.54 | 40.78 |
Book Value Per Share | 8.54 | 8.22 | 7.70 | -57.65 | -63.87 |
Tangible Book Value | 409.54 | 369.22 | 257.44 | -72.47 | -42.61 |
Tangible Book Value Per Share | 8.54 | 8.22 | 7.70 | -57.65 | -63.87 |
Machinery | 2.25 | 1.27 | 1.11 | 0.24 | 0.23 |
Construction In Progress | 2.55 | 1.62 | - | 0 | - |
Leasehold Improvements | 0.68 | 0.52 | 0.39 | 0.37 | 0.35 |